167 related articles for article (PubMed ID: 38519377)
1. The New WHO Category of "Molecularly Defined Renal Carcinomas": Clinical and Diagnostic Features and Management Implications.
Kanakaraj J; Chang J; Hampton LJ; Smith SC
Urol Oncol; 2024 Jul; 42(7):211-219. PubMed ID: 38519377
[TBL] [Abstract][Full Text] [Related]
2. New insights in the new WHO classification of adult renal tumors.
Hes O; Michalová K; Pivovarčíková K
Cesk Patol; 2022; 67(4):187-191. PubMed ID: 36513503
[TBL] [Abstract][Full Text] [Related]
3. The WHO 2022 Classification of Renal Neoplasms (5th Edition): Salient Updates.
Goswami PR; Singh G; Patel T; Dave R
Cureus; 2024 Apr; 16(4):e58470. PubMed ID: 38765391
[TBL] [Abstract][Full Text] [Related]
4. Genomic alterations and diagnosis of renal cancer.
Zhang X; Bolck HA; Rupp NJ; Moch H
Virchows Arch; 2024 Feb; 484(2):323-337. PubMed ID: 37999735
[TBL] [Abstract][Full Text] [Related]
5. Clinico-pathological implications of the 2022 WHO Renal Cell Carcinoma classification.
Rizzo M; Caliò A; Brunelli M; Pezzicoli G; Ganini C; Martignoni G; Camillo P
Cancer Treat Rev; 2023 May; 116():102558. PubMed ID: 37060647
[TBL] [Abstract][Full Text] [Related]
6. What's new in the WHO 2022 classification of kidney tumours?
Alaghehbandan R; Siadat F; Trpkov K
Pathologica; 2022 Feb; 115(1):8-22. PubMed ID: 36645398
[TBL] [Abstract][Full Text] [Related]
7. TFE3 and TFEB-rearranged renal cell carcinomas: an immunohistochemical panel to differentiate from common renal cell neoplasms.
Caliò A; Marletta S; Brunelli M; Pedron S; Portillo SC; Segala D; Bariani E; Gobbo S; Netto G; Martignoni G
Virchows Arch; 2022 Dec; 481(6):877-891. PubMed ID: 35980471
[TBL] [Abstract][Full Text] [Related]
8. The 2022 World Health Organization Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours.
Moch H; Amin MB; Berney DM; Compérat EM; Gill AJ; Hartmann A; Menon S; Raspollini MR; Rubin MA; Srigley JR; Hoon Tan P; Tickoo SK; Tsuzuki T; Turajlic S; Cree I; Netto GJ
Eur Urol; 2022 Nov; 82(5):458-468. PubMed ID: 35853783
[TBL] [Abstract][Full Text] [Related]
9. Reappraisal of Morphologic Differences Between Renal Medullary Carcinoma, Collecting Duct Carcinoma, and Fumarate Hydratase-deficient Renal Cell Carcinoma.
Ohe C; Smith SC; Sirohi D; Divatia M; de Peralta-Venturina M; Paner GP; Agaimy A; Amin MB; Argani P; Chen YB; Cheng L; Colecchia M; Compérat E; Werneck da Cunha I; Epstein JI; Gill AJ; Hes O; Hirsch MS; Jochum W; Kunju LP; Maclean F; Magi-Galluzzi C; McKenney JK; Mehra R; Nesi G; Osunkoya AO; Picken MM; Rao P; Reuter VE; de Oliveira Salles PG; Schultz L; Tickoo SK; Tomlins SA; Trpkov K; Amin MB
Am J Surg Pathol; 2018 Mar; 42(3):279-292. PubMed ID: 29309300
[TBL] [Abstract][Full Text] [Related]
10. Update on Selected High-grade Renal Cell Carcinomas of the Kidney: FH-deficient, ALK-rearranged, and Medullary Carcinomas.
Chen YB
Adv Anat Pathol; 2024 Mar; 31(2):118-125. PubMed ID: 38145398
[TBL] [Abstract][Full Text] [Related]
11. [WHO classification 2016 and first S3 guidelines on renal cell cancer: What is important for the practice?].
Moch H
Pathologe; 2016 Mar; 37(2):127-33. PubMed ID: 26942728
[TBL] [Abstract][Full Text] [Related]
12. New entities, new technologies, new findings: A review of the cytologic features of recently established subtypes of renal cell carcinoma.
Robila V; Kraft AO; Smith SC
Cancer Cytopathol; 2019 Feb; 127(2):79-97. PubMed ID: 30690877
[TBL] [Abstract][Full Text] [Related]
13. How New Developments Impact Diagnosis in Existing Renal Neoplasms.
Akgul M; Williamson SR
Surg Pathol Clin; 2022 Dec; 15(4):695-711. PubMed ID: 36344184
[TBL] [Abstract][Full Text] [Related]
14. Report From the International Society of Urological Pathology (ISUP) Consultation Conference on Molecular Pathology of Urogenital Cancers: III: Molecular Pathology of Kidney Cancer.
Williamson SR; Gill AJ; Argani P; Chen YB; Egevad L; Kristiansen G; Grignon DJ; Hes O
Am J Surg Pathol; 2020 Jul; 44(7):e47-e65. PubMed ID: 32251007
[TBL] [Abstract][Full Text] [Related]
15. Pathology of renal cell carcinoma: an update.
Lopez-Beltran A; Cheng L; Vidal A; Scarpelli M; Kirkali Z; Blanca A; Montironi R
Anal Quant Cytopathol Histpathol; 2013 Apr; 35(2):61-76. PubMed ID: 23700715
[TBL] [Abstract][Full Text] [Related]
16. A
Smith SC; Yu J; Paul AK
Int J Surg Pathol; 2024 May; 32(3):539-542. PubMed ID: 37415407
[TBL] [Abstract][Full Text] [Related]
17. The new WHO 2022 category of molecularly defined renal carcinomas: Accessible to practicing pathologists.
Smith SC; Wobker SE
Am J Clin Pathol; 2023 Dec; 160(6):545-548. PubMed ID: 37589571
[No Abstract] [Full Text] [Related]
18. Renal medullary carcinomas: histopathologic phenotype associated with diverse genotypes.
Gatalica Z; Lilleberg SL; Monzon FA; Koul MS; Bridge JA; Knezetic J; Legendre B; Sharma P; McCue PA
Hum Pathol; 2011 Dec; 42(12):1979-88. PubMed ID: 21733559
[TBL] [Abstract][Full Text] [Related]
19. The classification of pediatric and young adult renal cell carcinomas registered on the children's oncology group (COG) protocol AREN03B2 after focused genetic testing.
Cajaiba MM; Dyer LM; Geller JI; Jennings LJ; George D; Kirschmann D; Rohan SM; Cost NG; Khanna G; Mullen EA; Dome JS; Fernandez CV; Perlman EJ
Cancer; 2018 Aug; 124(16):3381-3389. PubMed ID: 29905933
[TBL] [Abstract][Full Text] [Related]
20. Minimally invasive cytologic evaluation leading to the diagnosis of TFE3-rearranged renal cell carcinoma: A case report.
Gama A; Sukhanova M; Choy B
Diagn Cytopathol; 2022 Dec; 50(12):E382-E385. PubMed ID: 35975764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
